<DOC>
	<DOCNO>NCT00002057</DOCNO>
	<brief_summary>To determine safe , effective , convenient dose schedule nystatin pastilles prevention oral candidiasis patient AIDS AIDS relate complex ( ARC ) ( group III IV , CDC classification ) .</brief_summary>
	<brief_title>Nystatin Pastilles Prevention Oral Candidiasis Patients With AIDS ARC</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Oral</mesh_term>
	<mesh_term>Nystatin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Systemic oral antibiotic . Experimental drug ( IND drug ) target specifically AIDS ( group IV CDC classification ) virus stimulate immune system . Patients follow condition include : AIDS AIDS relate complex ( ARC ) ( HIV infection Group 3 4 , CDC classification ) cultureproven oral candidiasis clinically cure within 7 day study entry likely compliant 20 week nystatin pastille prophylaxis . Able follow instruction regard use pastille . Patients enter part II study ( randomize doubleblind ) must clinically cure oral candidiasis within 1 7 day entry randomize study . Oral lesion Kaposi 's sarcoma , herpes zoster , herpes simplex enrol . Exclusion Criteria Coexisting Condition : Patients follow exclude : Systemic candidiasis . Hypersensitivity nystatin . Suspected proven candidal esophagitis . Patients follow exclude : Systemic candidiasis . Projected survival le 6 month . Unable maintain pastille buccal cavity approximately 20 minute twice day . Hypersensitivity nystatin . Suspected proven candidal esophagitis .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Nystatin</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Candidiasis , Oral</keyword>
</DOC>